Absci (ABSI) Acquisitions (2021 - 2022)
Absci (ABSI) posted Acquisitions of $8.0 million for Q2 2022, down 68.77% sequentially from $25.6 million in Q2 2021, and down 68.77% YoY from $25.6 million in Q2 2021.
Powered by 
Analysis
Absci (ABSI) Acquisitions (2021 - 2022) Analysis & Trends
Absci has reported Acquisitions for 2 years, with the latest figure at $8.0 million in Q2 2022.
- Quarterly Acquisitions fell 68.77% year-over-year to $8.0 million in Q2 2022, while the trailing twelve-month figure through Sep 2023 was $8.0 million (changed 0.0% YoY) and the FY2022 annual result came in at $8.0 million, down 71.56% from the prior year.
- Acquisitions retreated to $8.0 million in Q2 2022 per ABSI's latest filing, from $25.6 million in the prior quarter.
- Over five years, Acquisitions peaked at $25.6 million in Q2 2021 and troughed at $2.5 million in Q1 2021.
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Acquisitions (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 138.47 Bn | 130.62 Bn | 2.84 Bn | - |
| 2 | Regeneron Pharmaceuticals | 85.18 Bn | 77.19 Bn | 3.93 Bn | - |
| 3 | Argenx Se | 63.38 Bn | 58.19 Bn | 1.37 Bn | - |
| 4 | Moderna | 58.09 Bn | 52.95 Bn | 52.00 Mn | - |
| 5 | Revolution Medicines | 44.33 Bn | 44.33 Bn | - | - |
| 6 | BeOne Medicines | 40.02 Bn | 34.92 Bn | 1.53 Bn | - |
| 7 | Alnylam Pharmaceuticals | 35.57 Bn | 32.27 Bn | 992.69 Mn | - |
| 8 | Royalty Pharma | 28.45 Bn | 27.61 Bn | - | - |
| 9 | Insmed | 27.48 Bn | 26.32 Bn | 358.27 Mn | - |
| 10 | Absci | 1.39 Bn | 1.19 Bn | - | - |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Jun 30, 2022 | 8.00 Mn |
| Jun 30, 2021 | 25.62 Mn |
| Mar 31, 2021 | 2.51 Mn |